Research Article
Association of Septic Shock with Mortality in Hospitalized COVID-19 Patients in Wuhan, China
Table 3
Treatments, complications, and clinical outcome.
| | | All patients | Clinical outcomes | value | | Septic shock | Nonseptic shock | | 212 | 30 | 182 |
| | Treatment | | | | | | Antiviral therapy—No. (%) | | | | | | Oseltamivir | 143/212 (67.5) | 23/30 (76.7) | 120/182 (65.9) | 0.245 | | Ganciclovir | 144/212 (67.9) | 21/30 (70) | 123/182 (67.6) | 0.793 | | Arbidol | 153/212 (72.2) | 17/30 (56.7) | 136/182 (74.7) | 0.041 | | Kaletra | 23/212 (10.8) | 11/30 (36.7) | 12/182 (6.6) | ≤0.001 | | Interferon | 15/212 (7.1) | 4/30 (13.3) | 11/182 (6) | 0.228 | | Antibiotic therapy—No. (%) | | | | | | Antibiotics | 202/212 (95.3) | 29/30 (96.7) | 173/182 (95.1) | 1.000 | | Use of corticosteroid/glucocorticoid therapy—No. (%) | | | | | | Corticosteroid/glucocorticoid | 137/212 (64.6) | 27/30 (90) | 110/182 (60.4) | 0.002 | | Continuous renal replacement therapy—No. (%) | | | | | | Oxygen support—No. (%) | | | | | | Nasal cannula | 210/212 (99.1) | 29/30 (96.7) | 181/182 (99.5) | 0.276 | | Noninvasive ventilation (NIV) | 33/212 (15.6) | 27/30 (90) | 6/182 (3.3) | <0.001 | | Invasive ventilation (IV) | 19/212 (9) | 17/30 (56.7) | 2/182 (1.1) | <0.001 | | Complication—No. (%) | | | | | | Acute cardiac injury | 37/212 (17.5) | 24/30 (80) | 13/182 (7.1) | <0.001 | | Arrhythmia | 21/212 (9.9) | 18/30 (60) | 3/182 (1.6) | <0.001 | | Acute respiratory distress syndrome | 76/212 (35.8) | 28/30 (93.3) | 48/182 (26.4) | <0.001 | | Acute kidney injury | 11/212 (5.2) | 9/30 (30) | 2/182 (1.1) | <0.001 | | Acute respiratory injury | 76/212 (35.8) | 29/30 (96.7) | 47/182 (25.8) | <0.001 | | Secondary infection | 9/212 (4.2) | 8/30 (26.7) | 1/182 (0.5) | <0.001 |
|
|
